MEMBERS

If you are a member of the network, please log in to access Network content and tools. If you do not have a username, contact your site principal investigator or site coordinator and request that they complete a membership request for you. If you have forgotten your password, you may CLICK HERE.


AS ATN

You are here

Therapy and Medication Use in Young Children with Autism: A Secondary Data Analysis from the Autism Speaks Autism Treatment Network (ATN).

TitleTherapy and Medication Use in Young Children with Autism: A Secondary Data Analysis from the Autism Speaks Autism Treatment Network (ATN).
Publication TypeConference Abstract
Year of Publication2016
AuthorsZiskind, D, Bennett, AE, Jawad, A, Blum, NJ
Conference NameIMFAR.
Abstract

Background: Guidelines suggest that young children with Autism Spectrum Disorder (ASD) should receive intensive psychosocial interventions. Additionally, associated symptoms may be treated with psychotropic medications. However, actual intervention use by young children with ASD has not been well characterized.

Objectives: The aim of this study was to describe interventions received by young children (aged 36-72 months) with ASD ≥6 months after diagnosis. The association with socio-demographic factors was also explored.

Methods: Data were used from the Autism Speaks Autism Treatment Network (ATN), a research registry of children with ASD which includes 17 sites in the U.S. and Canada. AS-ATN participants undergo a standardized diagnostic evaluation and receive treatment recommendations from Autism specialists. Parents report services and medications being used at follow-up visits.

Results: Most young children (91.4%) received psychosocial interventions but only 36% received behavioral-based therapy. The median total hours per week of therapy was only 5.0 hours (range 0-65; interquartile range 1.5-14) and of those who received behavioral-based therapies, the median hours per week received was only 4.6 hours (range 0.1-50, interquartile range: 2-12). Demographic factors found to be associated with increased total therapy intensity included younger age, non-Hispanic/ Latino ethnicity, higher parental educational level and geographic location in the Northeast or Southern U.S. Additionally, 22.4% of subjects were on ≥1 psychotropic medication and the most commonly prescribed medications were α-agonists Demographic factors found to be associated with increased psychotropic medication use included older age, Black/ African American race, lower parental education and living in Canada.

Conclusions: Relatively few young children with ASD are receiving evidence-based behavioral therapies and few are receiving psychosocial interventions at the recommended intensity. There is significant regional and socio-demographic variability in psychosocial intervention and psychotropic medication use. Additionally, the class of medications most commonly prescribed has not been extensively studied in this population. Further research is needed to support current prescribing practices and to improve access to evidence-based treatments for young children with ASD.